The rapid progress in biomarker science is on the threshold of significantly changing clinical care for infants in the neonatal ICU. Infants with neonatal brain injuries will likely be the first group whose management is dramatically altered with point-of-care, rapidly available brain biomarker analysis. Providing an interim update on progress in this area is the purpose of this review.
INTRODUCTION
Hypothermia is currently the only recognized standard of care treatment for moderate-to-severe perinatal hypoxic-ischemic encephalopathy (HIE), but about 45% of neonates have abnormal outcomes despite treatment [1] . Management of neonates with HIE is hindered by the lack of quantifiable biomarkers that could measure the degree of injury, assist in triage to therapy and give prognostic information. Currently, the diagnosis and prognosis of HIE in a neonate is based on clinical manifestations, imaging and electrophysiological monitoring [2] . MRI biomarkers for HIE have generally been performed several days following birth because of the lack of early sensitivity for hypoxic injury, and MRI requires that the infant be moved from the neonatal ICU (NICU) to the imaging suite, a task that can be difficult under certain circumstances. Both of these can be overcome with the use of head ultrasound (HUS) as an imaging biomarker [3 & ]; however, HUS is not well tested nor universally accepted for this purpose because of lower sensitivity [4 & ]. Biochemical evaluation of the severity of birth asphyxia has traditionally been performed using umbilical arterial blood gases at birth, but this test is poorly predictive of injury. Taken together, these constraints make long-term neurodevelopmental outcome difficult to predict in the first few days of life. Multiorgan involvement, although common when brain injury occurs, is not part of the diagnosis of HIE. In the presence of HIE, the most frequently injured organs are the heart, liver, kidneys and hematological system which may release organ-specific biomarkers into the blood which will have a role in the assessment of injury severity and long-term outcome [ ]. It appears from this report that therapeutic hypothermia was not used in the treatment of these infants; thus, cardiac depression from cooling should not have interfered with the interpretation. Phenobarbital was used liberally; however, there is no analysis for this as a confounder.
Post-hoc analysis of glycemic control in 234 neonates with moderate-to-severe HIE from the CoolCap study showed that both hypoglycemia and hyperglycemia were independently associated with unfavorable outcome. Any glucose derangement during the early postnatal period in infants with moderate-tosevere HIE was independently associated with an unfavorable outcome at 18 months, independent of severity of HIE and cooling therapy [11] . Lactate dehydrogenase (LDH), an enzyme that exists in all cells and is released into the plasma by cellular damage, has been investigated as an inexpensive and well tolerated prognostic biomarker in neonates with HIE [12 & ]. A study of 92 neonates with HIE found that although LDH levels did not differ for those with brain lesions on MRI, the change in LDH was significantly higher on day 3 of life in neonates with central gray matter lesions, which led these investigators to claim that changes in serum LDH may be a useful biomarker for predicting future neurodevelopmental prognosis in infants with HIE [12 & ].
METABOLIC PROFILING OF NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY
When mass spectrometry was applied to provide metabolic profiles of brain tissue and plasma
KEY POINTS
Although new single biomarker studies continue to emerge, utilizing metabolomic profiling to more comprehensively understand the effects of injury and treatment on entire pathways following neonatal brain injury may identify new therapeutic targets in neonatal brain injury.
A number of biomarkers used to identify other conditions are now being used to identify neonatal neurologic injury. Markers of cardiac injury are increasingly useful in this respect.
Cytokine biomarkers in a relevant preclinical model of HIE identify a proinflammatory surge during the rewarming period following therapeutic hypothermia. If confirmed, these studies may reveal an additional therapeutic target in neonatal HIE.
Until recently, very few biomarker studies in neonatal brain injury included posthospital outcomes. Future studies will need to include these data to provide maximal information about their utility.
following an excitotoxic lesion to the neonatal mouse brain, it was found that a short list of amino acids and glycerophospholipids explained the effects of the excitotoxic lesion [13 && ]. These investigators concluded that these targets may be useful starting points for studies on acute and tertiary phase biomarkers specific to the excitotoxic processes [13 && ]. In a newborn piglet model of HIE, time-dependent metabolic biomarker profiles of choline, betaine, cytidine and uridine were observed to have patterns similar to lactate levels, which are currently considered the gold standard for assessing hypoxia, and they concluded that the prediction of injury could be improved with the use of a combination of plasma metabolites [14 && ]. A metabolite score calculated based on the relative intensities of three metabolites (choline, 6,8-dihydroxypurine and hypoxanthine) was compared with lactate as a biomarker for the intensity and duration of perinatal hypoxia in a neonatal piglet model [15 && ]. For plasma samples drawn before and directly after a hypoxic insult, the metabolite score performed similar to lactate, but it provided better predictive capacity at 2 h after resuscitation. Serial determinations of such a score in a minimally invasive biofluid may improve the early assessment of the severity of the hypoxic insult and assist in the diagnosis and triage to treatment [15 && ]. In a nonhuman primate model using in-utero umbilical cord occlusion to induce HIE, 63 metabolites were examined as potential biomarkers of brain injury. Of this group, eight (arachidonic acid, botanic acid, citric acid, fumaric acid, lactate, maleate propanoic acid and succinic acid) were identified that correlated with early and/or long-term neurodevelopmental outcomes [16] . When hypoxia and hypotension were induced in newborn piglets, the plasma metabolome showed an increased plasma concentration of analytes reflecting a metabolic adaptation to prolonged anaerobiosis; however, after resuscitation, metabolite levels returned to the starting values [17 & ]. Choline was the most significantly increased analyte during the hypoxic insult, and they concluded that these metabolites could have applicability in predicting the severity of hypoxia in the clinical setting [17 
INFLAMMATORY BIOMARKERS OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY
Cytokine and chemokine levels may be specific to the phase of injury and recovery, switching roles within a relatively short time after hypoxia-ische- A prospective randomized pilot study of newborns delivered after more than 36 weeks to selective head cooling or whole body cooling found that the effects on biomarkers did not differ. They also found that serum IL-6 levels may be useful for predicting disability and mortality in newborns with HIE [20] .
NEW BIOMARKERS FOR HYPOXIC-ISCHEMIC ENCEPHALOPATHY
Recent studies have identified a number of biomarkers that may improve identification of neonatal neurologic injury in the period shortly after birth. Studies in 10-day-old mice reveal that hypoxia-ischemia significantly increases osteopontin, a finding not observed after lipopolysaccharide administration [21 & ]. Osteopontin mRNA was induced in the brain but not in the blood, and immunostaining revealed osteopontin expression by microglia/macrophages in the hypoxia-ischemia-injured brain. They concluded that osteopontin may be a prognostic blood biomarker in HIE related to brain microglial activation, and that an increase of plasma osteopontin may indicate a perinatal event at least 24-h old. Therefore, it might be useful as a marker of prior intrauterine hypoxiaischemia stress and a poorer response to hypothermia treatment 
Oxidative stress is a crucial step in the development of HIE, and biomarkers such as lipid peroxidation products have been found to be increased in cord blood at delivery with severe metabolic acidosis [27 && ]. Selenium is a constituent of the antioxidant enzyme glutathione peroxidase and is vital to antioxidant defense. Neonates with HIE have been found to have lower serum selenium levels than normal healthy neonates, independent of maternal levels, and selenium levels were negatively correlated with the severity of HIE [28] .
NEW TECHNOLOGIES IN BIOMARKER DETECTION
The development of novel methodologies to detect brain injury proteins with improved sensitivity and speed may provide results that are clinically actionable. Breakthroughs in digital ELISA assays such as the Simoa platform (Quanterix, Lexington, Massachusetts, USA) allow femptogram/microliter detection of brain proteins such as Tau [29] . Advances are also being made in developing rapid detection biosensor platforms that may enable bedside detection of brain injury proteins. Organic field effect transistors have already demonstrated less than 3-min detection of glial fibrillary acidic protein (GFAP) [30, 31] . Alternatively, silicon nanowires coated with detection antibodies also have the potential for protein detection within 2 min [32] . These platforms have the potential to revolutionize how we care for neonatal brain injury.
NEURODEVELOPMENTAL FOLLOW-UP FOR PREVIOUSLY STUDIED BRAIN INJURY BIOMARKERS
Only recently have studies evaluated neurodevelopmental follow-up associated with biomarkers found to be associated with neonatal brain injury during the perinatal period. In neonates born at more than 35 weeks with HIE, serum lactate levels measured after 72 h of whole body hypothermia correlated with neurodevelopmental outcome at 24-month corrected age [33] . Although IL-6 and IL-16 measured in umbilical cord blood at birth were correlated with HIE severity, IL-6 did not show any association with outcome at the age of 3 years [34 ] . Prior studies have shown GFAP measured in neonatal blood at 1-2 and 4-7 days of life (but not in cord blood) were associated with abnormal brain MRI at 7-10 days of life [35] . Furthermore, GFAP levels at time of NCU admission were significantly higher in those infants with feeding abnormalities at time of NICU discharge [35] . Chalak et al. [36] also demonstrated that GFAP in neonates with moderate-to-severe HIE was elevated at birth and associated with abnormal neurologic outcomes. Looney et al. [37] utilizing a different laboratory assay, noted that GFAP measured in cord blood at birth was not increased in those with brain injury compared with healthy controls, and no correlation was found between cord blood levels of GFAP and outcome at 36 months. These data point out the potential exquisite time dependence of the biomarker in relation to time of injury.
CONCLUSION
Given the variation of causes and symptoms at presentation of neonatal HIE, it is unlikely that a single early biomarker will be able to predict clinical outcomes in the perinatal period [8
. A panel of multiple inflammatory and neuronal biomarkers measured via a point of care bedside tool at various time points is likely to be the most accurate way to identify and assess the severity, timing and pattern of injury. Furthermore, full pathway analysis via various-omic strategies may identify new therapeutic targets for neonatal hypoxia-ischemia brain injury. Neonatal brain biomarker research is currently in its very early development with major advances still to be made. 196. The reviews quantitative serum biomarkers that could improve the precision in identifying intapartum fetal hypoxia-ischemia, the neonatal diagnosis of HIE and measure the effectiveness of treatment for HIE.
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